DCTHDelcath Systems Inc.Running, no new patients
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Metastatic Ocular Melanoma · Metastatic Uveal Melanoma
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Mar 2024, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 30 (planned)
- Started
- Jun 10, 2022
- Main results expected
- Mar 1, 2024
- Fully finished
- Mar 1, 2024
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adverse Events
Measured over: From eligibility until death due to any cause, for up to 104 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2024-03-01, no fading
Raw record changes
- none yet
Trial ID NCT05022901 · record last updated 2023-12-21 · checked 2026-11-09 15:47 UTC